{"id":1009124,"date":"2026-10-12T06:33:09","date_gmt":"2026-10-12T10:33:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/"},"modified":"2026-10-12T06:33:09","modified_gmt":"2026-10-12T10:33:09","slug":"enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/","title":{"rendered":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold<\/b><\/p>\n<p class=\"bwalignc\"><i>102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve\u2122 Resorbable Magnesium Scaffolds in long coronary lesions<\/i><\/p>\n<p>WAYNE, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTeleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07091682%3Fterm%3DBIOMAG%2520LL%26viewType%3DCard%26rank%3D1&amp;esheet=54619328&amp;newsitemid=20261012745636&amp;lan=en-US&amp;anchor=BIOMAG%26%238482%3B-LL+Clinical+Study&amp;index=1&amp;md5=20313880105a4c60ca783a01fcefbd76\">BIOMAG\u2122-LL Clinical Study<\/a>, evaluating the safety and clinical performance of the Freesolve\u2122 Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex&#8217;s commitment to expanding clinical evidence supporting the use of the Freesolve\u2122 RMS in percutaneous coronary intervention (PCI).<\/p>\n<p>\nBIOMAG\u2122-LL Clinical Study is a premarket, prospective, international, multi-center, single arm trial. The primary endpoint of the study is Target Lesion Failure* (TLF) rate at 12 months, a composite clinical endpoint commonly used to assess the safety and effectiveness of coronary interventional devices. Clinical follow-up is conducted at 1, 6, 12, 36, and 60 months post-procedure.<\/p>\n<p>\n\u201cIn the increasingly prevalent setting of diffuse coronary artery disease, we want to avoid long, permanent stented segments where possible,\u201d said Prof. Flavio Ribichini, Interventional Cardiologist.<sup>\u2020<\/sup> \u201cThe data generated by the BIOMAG\u2122-LL Clinical Study will help determine whether longer Freesolve\u2122 Scaffolds can expand treatment options for patients with longer lesions while supporting the broader evolution of resorbable scaffold therapy.\u201d<\/p>\n<p>\nThe availability of longer scaffold lengths has the potential to provide physicians with additional treatment options for long lesions, reducing the need for permanent implants and potentially offering an alternative to drug-coated balloons where temporary scaffolding is required to support the vessel wall.<\/p>\n<p>\n&#8220;We are pleased to announce the successful completion of enrollment in the BIOMAG\u2122-LL Clinical Study,&#8221; said Prof. Dr. Georg Nollert, Vice President Medical Affairs at Teleflex. &#8220;The study represents an important step in expanding the Freesolve\u2122 RMS portfolio to address longer coronary lesions while maintaining the performance characteristics of our resorbable magnesium scaffold technology.&#8221;<\/p>\n<p>\nIn addition, the 35 mm and 40 mm Freesolve\u2122 Scaffold lengths are included in the ongoing <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07258290%3Fterm%3DBIOMAG-III%26viewType%3DCard%26rank%3D1&amp;esheet=54619328&amp;newsitemid=20261012745636&amp;lan=en-US&amp;anchor=BIOMAG%26%238482%3B-III+Pivotal+Clinical+Trial&amp;index=2&amp;md5=f049b8af2496b9ce89b5b0dcdea306dd\">BIOMAG\u2122-III Pivotal Clinical Trial<\/a>, which is currently enrolling patients in the United States and other international markets.<\/p>\n<p>\nLong coronary lesions remain among the more challenging lesion subsets in PCI, often requiring multiple devices or overlapping implants to achieve complete lesion coverage. Longer resorbable scaffold lengths may enable treatment of longer lesions with fewer implants, potentially simplifying procedures and reducing scaffold overlap. The BIOMAG\u2122-LL Clinical Study is expected to provide important evidence regarding the use of 35 mm and 40 mm Freesolve\u2122 Scaffolds in lesions up to 38 mm. The data could support broader treatment options for patients with diffuse coronary artery disease, further advancing the clinical application of resorbable magnesium scaffold technology.<\/p>\n<p><b>Expanding the Freesolve\u2122<\/b><sup \/><b>RMS Size Matrix<\/b><\/p>\n<p>\nThe 35 mm and 40 mm scaffold lengths evaluated in BIOMAG\u2122-LL Clinical Study are designed to complement the current Freesolve\u2122<sup \/>RMS size matrix, which offers diameters of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm, and lengths of 13 mm, 18 mm, 22 mm, 26 mm and 30 mm. Freesolve\u2122 RSM is commercially available in CE-mark accepting countries only.<\/p>\n<p><b>About Teleflex Incorporated<\/b><\/p>\n<p>\nAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people\u2019s lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.<\/p>\n<p>\nTeleflex is the home of Arrow\u2122, Barrigel\u2122, Deknatel\u2122, LMA\u2122, Pilling\u2122, QuikClot\u2122, R\u00fcsch\u2122, UroLift\u2122 and Weck\u2122 \u2013 trusted brands united by a common sense of purpose.<\/p>\n<p>\nAt Teleflex, we are empowering the future of healthcare. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fteleflex.com%2Fusa%2Fen%2F&amp;esheet=54619328&amp;newsitemid=20261012745636&amp;lan=en-US&amp;anchor=teleflex.com&amp;index=3&amp;md5=7a8af414c04f8fb5b88af5e11d6ee0de\">teleflex.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management&#8217;s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.<\/p>\n<p><i>Teleflex, the Teleflex logo, Arrow, Barrigel, BIOMAG, Deknatel, Freesolve, LMA, Pilling, QuikClot, R\u00fcsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and\/or other countries.<\/i><i>Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative \u00a9 2026 Teleflex Incorporated. All rights reserved. MC-012466 Rev 0. Revised 10\/2026.<\/i><\/p>\n<p>\n* Target Lesion Failure (TLF) is a standard composite measure of device safety and effectiveness that includes cardiac death, Target Vessel Q-wave or non-Q wave Myocardial Infarction, and clinically-driven target lesion revascularization.<\/p>\n<p><sup>\u2020<\/sup>Prof. Flavio Ribichini is a paid consultant of Teleflex.<\/p>\n<p>\nCAUTION\u2014Investigational device. Limited by the United States law to investigational use.<\/p>\n<p>\nFreesolve\u2122 RMS is not approved for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location.<\/p>\n<p>\nFreesolve\u2122 RMS is clinically often referred to as DREAMS 3G RMS.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261012745636\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261012745636\/en\/<\/a><\/span><\/p>\n<p>\nTeleflex<br \/>\n<br \/>Lawrence Keusch<br \/>\n<br \/>Vice President, Investor Relations and Strategy Development<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor.relations@teleflex.com\">investor.relations@teleflex.com<br \/>\n<\/a><br \/>610-948-2836<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Pennsylvania<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Supplies Medical Devices Health Surgery Radiology Cardiology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261012745636\/en\/2710168\/3\/Teleflex_Global_Corporate_Brand_Logo_CMYK_Navy-White_%28002%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold 102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve\u2122 Resorbable Magnesium Scaffolds in long coronary lesions WAYNE, Pa.&#8211;(BUSINESS WIRE)&#8211; Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG\u2122-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve\u2122 Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex&#8217;s commitment to expanding clinical evidence supporting the use of the Freesolve\u2122 RMS in percutaneous coronary intervention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009124","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold 102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve\u2122 Resorbable Magnesium Scaffolds in long coronary lesions WAYNE, Pa.&#8211;(BUSINESS WIRE)&#8211; Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG\u2122-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve\u2122 Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex&#8217;s commitment to expanding clinical evidence supporting the use of the Freesolve\u2122 RMS in percutaneous coronary intervention &hellip; Continue reading &quot;Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-12T10:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold\",\"datePublished\":\"2026-10-12T10:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/\"},\"wordCount\":972,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/\",\"name\":\"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-12T10:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/","og_locale":"en_US","og_type":"article","og_title":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk","og_description":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold 102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve\u2122 Resorbable Magnesium Scaffolds in long coronary lesions WAYNE, Pa.&#8211;(BUSINESS WIRE)&#8211; Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG\u2122-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve\u2122 Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex&#8217;s commitment to expanding clinical evidence supporting the use of the Freesolve\u2122 RMS in percutaneous coronary intervention &hellip; Continue reading \"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-12T10:33:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold","datePublished":"2026-10-12T10:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/"},"wordCount":972,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/","name":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-12T10:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261012745636r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-completed-in-biomag-ll-clinical-study-evaluating-longer-lengths-for-freesolve-resorbable-magnesium-scaffold\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enrollment Completed in BIOMAG\u2122-LL Clinical Study Evaluating Longer Lengths for Freesolve\u2122 Resorbable Magnesium Scaffold"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009124"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}